The Oral Transition in Rare Disease Crisis Management: Deucrictibant, Bradykinin B2 Receptors, and the Next Phase of Acute HAE Care
Dr. Dereck Mush, MD, MBALife sciences
Pharma, biology platforms, drug discovery and the science that turns lab work into therapies and products.
Dr. Dereck Mush, MD, MBA
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
Beyond Gluten Avoidance: How argenx's CD122 Blockade Advances Pharmacological Protection in Celiac Disease
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
